Knight Therapeutics Inc. GUD.TO

GUD.TO Company Overview

Knight Therapeutics Inc. is a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, marketing, and commercializing prescription medicines, primarily for underserved or niche therapeutic markets. The company operates within the branded pharmaceutical and specialty healthcare industries, with a strategic emphasis on Latin America and Canada. Its revenue is primarily generated through the sale and distribution of branded pharmaceuticals, licensing agreements, and milestone or royalty-related arrangements tied to its product portfolio.

Knight Therapeutics was founded in 2014 by Jonathan Ross Goodman, who previously led Paladin Labs before its acquisition by Endo International. The company was established with a business model centered on capital-efficient pharmaceutical acquisitions and regional commercialization partnerships. Over time, Knight expanded from a Canada-focused specialty pharmaceutical platform into a broader pan-Latin American operation through acquisitions and regional investments. The company positions itself as a specialty pharmaceutical partner with strong regional infrastructure, local regulatory expertise, and an asset-light operating approach focused on in-licensed and acquired products rather than large-scale internal drug discovery.